logo

For the Inventor, By the Inventor

Des Plaines, IL, United States of America

Abbott Molecular Inc.


USPTO Granted Patents = 97

% Expired Patents = 40.2



Trademarks = 8

Forward Citations = 213

Loading Chart...
Loading Chart...

139 inventors (with patents filed for the assignee):

goldMedal Shihai X Huang (17 out of 18 patents)

silverMedal Gerard J Gundling (14 out of 17 patents)

bronzeMedal Ekaterina Pestova (11 out of 11 patents)

4.  Larry E Morrison (11 out of 42 patents)

5.  Ning Tang (10 out of 11 patents)

6.  Klara Abravaya (10 out of 14 patents)

7.  Irina A Sokolova (9 out of 16 patents)

8.  Dae Hyun Kim (7 out of 26 patents)

9.  Gregor W Leckie (7 out of 7 patents)

10.  John A Salituro (7 out of 13 patents)

11.  Hong Wang (6 out of 6 patents)

12.  Sonal Sadaria Nana (6 out of 7 patents)

13.  Wai-Bing X Mak (6 out of 6 patents)

14.  Herbert A Marble (6 out of 6 patents)

15.  Mark A Talmer (6 out of 46 patents)


Core Competencies:
Nucleic Acid Extraction
Automated Analysis
HPV Detection
Nucleotide Analogs
PCR Techniques
Next-Generation Sequencing
Cancer Diagnostics
Sample Processing
Hybridization Probes
Drug Resistance
Chromosomal Abnormalities
Tuberculosis Detection

97 patents:

1. 12241131 - Methods and systems of multi-assay processing and analysis (2025-03-04),
2. 12234448 - Purification of nucleic acids using titanium oxides (2025-02-25),
3. 12025630 - Systems and methods for automated analysis (2024-07-02),
4. 12018328 - Assay for detecting human papilloma virus (HPV) (2024-06-25),
5. 12018248 - Sample processing devices, systems and methods (2024-06-25),
6. 11932911 - Compositions and methods for the detection and analysis of (2024-03-19),
7. 11608496 - Purification of nucleic acids using copper-titanium oxides (2023-03-21),
8. 11441194 - Methods and probe combinations for detecting melanoma (2022-09-13),
9. 11384398 - Assay for detecting human papilloma virus (HPV) (2022-07-12),
10. 11279982 - EGFR assay (2022-03-22),
11. 11274086 - Amplification of nucleic acids (2022-03-15),
12. 11225693 - Compositions and methods for identifying drug resistant tuberculosis (2022-01-18),
13. 11215628 - Methods of automatized sample loading and processing and devices and systems related thereto (2022-01-04),
14. 11136631 - Assay for detecting human immunodeficiency virus (HIV) (2021-10-05),
15. 11130983 - Sample preparation cartridges and methods for using same (2021-09-28),
Company Overview
Abbott Molecular Inc., based in Des Plaines, Illinois, specializes in nucleic acid detection technologies. The company focuses on developing and manufacturing advanced solutions for nucleic acid extraction, automated analysis, and cancer diagnostics. Its expertise encompasses a range of core technologies, including HPV detection, PCR techniques, next-generation sequencing, and sample processing. Abbott Molecular is committed to enhancing diagnostic capabilities and improving patient outcomes through innovative molecular testing solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Abbott Molecular Inc. USPTO Patent Assignee Logo
97 Patents

#5 in Des Plaines, IL

#221 in Illinois

#3,887 in US

#7,981 in the World

Des Plaines, IL (US)
Des Plaines, IL, United States of America

Abbott Molecular Inc.

Forward Citations = 213

139 inventors:

goldMedal Shihai X Huang (17 out of 18 patents)

silverMedal Gerard J Gundling (14 out of 17 patents)

bronzeMedal Ekaterina Pestova (11 out of 11 patents)

4.  Larry E Morrison (11 out of 42 patents)

5.  Ning Tang (10 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Abbott Molecular Inc.. Retrieved from https://idiyas.com/company/abbott-molecular

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…